Biochemical diagnosis, localization and management of pheochromocytoma: Focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour

Journal of Internal Medicine

Volumn 257, Issue 1, 2005, Pages 60-68

  Pacak, K ^a   Ilias, Ioannis ^a,b   Adams, K T ^a   Eisenhoffer, G ^c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF PATRAS   (Greece)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Computerized tomography; Magnetic resonance imaging; Metanephrines; Multiple endocrine neoplasia type 2; Pheochromocytoma; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE; ADRENALIN C 11; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBON 11; CARBOPLATIN; CATECHOLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXAZOSIN; DOXORUBICIN; ESMOLOL; ETOPOSIDE; FLUORINE 18; FLUORODOPAMINE F 18; HYDROXYEPHEDRINE C 11; LABETALOL; LIDOCAINE; METADRENALIN; METIROSINE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; SOMATOSTATIN RECEPTOR; TERAZOSIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADRENALECTOMY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER LOCALIZATION; CATECHOLAMINE METABOLISM; CATECHOLAMINE RELEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; HYPERTENSION; LAPAROSCOPIC SURGERY; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; SIPPLE SYNDROME; TACHYCARDIA;

ADRENAL GLAND NEOPLASMS; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METANEPHRINE; MULTIPLE ENDOCRINE NEOPLASIA; PHEOCHROMOCYTOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 12344286891     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01425.x     Document Type: Conference Paper

References (67)

1. Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP. The genetic basis of pheochromocytoma. Front Horm Res 2004; 31: 45-60.
2. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-71.
3. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 2003; 95: 1196-204.
4. Kaltsas GA, Papadogias D, Grossman AB. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res 2004; 31: 61-75.
5. Frank-Raue K, Kratt T, Hoppner W, Buhr H, Ziegler R, Raue F. Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene. Eur J Endocrinol 1996; 135: 222-5.
6. Ross JH. Pheochromocytoma. Special considerations in children. Urol Clin North Am 2000; 27: 393-402.
7. Eng C, Clayton D, Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276: 1575-9.
8. Eisenhofer G, Walther MM, Huynh TT et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86: 1999-2008.
9. Gagel RF, Marx SJ. Multiple endocrine neoplasia. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th edn. Philadelphia, USA: Saunders, 2003; 1717-62.
10. Dluhy RG, Lawrence EG, Williams GH. Endocrine hypertension. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th edn. Philadelphia, USA: Saunders, 2003; 552-86.
11. Pomares FJ, Canas R, Rodriguez JM, Hernandez AM, Parrilla P, Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf) 1998; 48: 195-200.
12. Gagel RF, Tashjaian AH, Cummings C et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A. An 18-year experience. N Engl J Med 1988; 318: 478-84.
13. Khorram-Manesh A, Ahlman H, Nilsson O, Oden A, Jansson S. Mortality associated with pheochromocytoma in a large Swedish cohort. Eur J Surg Oncol 2004; 30: 556-9.
14. Anon. Phaeochromocytoma unmasked by drug therapy. Prescrire Int 2003; 12: 181-2.
15. Neumann HP, Bausch B, McWhinney SR et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459-66.
16. Keiser HR. Pheochromocytoma and related tumors. In: DeGroot LJ, Jameson JL, eds. Endocrinology. Philadelphia, USA: Saunders, 2001; 1862-83.
17. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427-34.
18. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340: 1872-9.
19. Eisenhofer G, Lenders JW, Pacak K. Biochemical diagnosis of pheochromocytoma. Front Horm Res 2004; 31: 76-106.
20. Eisenhofer G, Goldstein DS, Walther MM et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656-66.
21. Bravo EL. Pheochromocytoma. Cardiol Rev 2002; 10: 44-50.
22. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004; 89: 479-91.
23. Caoili EM, Korobkin M, Francis IR et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002; 222: 629-33.
24. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 1998; 170: 747-52.
25. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21: 995-1012.
26. Dacie JE, White FE. Radiology of endocrine disease. In: Besser GM, Thorner MO, eds. Atlas of Endocrine Imaging. London, UK: Wolfe, 1993; 1-78.
27. Wafelman AR, Hoefnagel CA, Maessen HJ, Maes RA, Beijnen JH. Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours. Eur J Nucl Med 1997; 24: 544-52.
28. 111In] DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy. Acta Radiol 1994; 35: 53-7.
29. Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994; 35: 1753-7.
30. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43: 217-23.
31. van der Harst E, de Herder WW, Bruining HA et al. [(123)I] metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86: 685-93.
32. Kaltsas G, Korbonits M, Heintz E et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86: 895-902.
33. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212: 35-41.
34. Trampal C, Engler H, Juhlin C, Bergstrom M, Langstrom B. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology 2004; 230: 423-8.
35. Shulkin BL, Wieland DM, Schwaiger M et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992; 33: 1125-31.
36. Hoegerle S, Nitzsche E, Altehoefer C et al. Pheochromocytomas: detection with 18F DOPA whole body PET - initial results. Radiology 2002; 222: 507-12.
37. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38: 6-8.
38. Hovevey-Sion D, Eisenhofer G, Kopin IJ et al. Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats. Neuropharmacology 1990; 29: 881-7.
39. Ilias I, Yu J, Carrasquillo JA et al. Superiority of 6-[18F]- fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003; 88: 4083-7.
40. Ilias I, Yu J, Chen CC, Carrasquillo J, Whatley M, Pacak K. Comparison of 6-[18F]-Fluorodopamine Positron Emission Tomography with [123I]- Metaiodobenzylguanldine and [111In]-Pentetreotide Scintigraphy in the Localization of Pheochromocytoma. Paper presented at ENDO 2004, 86th Annual Meeting of the Endocrine Society; 16-19 June 2004. New Orleans, LA, USA: Endocrine Society, 2004; 452-3.
41. Epelbaum J, Bertherat J, Prevost G et al. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extra-adrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 1995; 80: 1837-44.
42. Reubi JC, Wasser B, Khoshla S, Kvols L, Krenning E, Lamberts SW. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 1992; 74: 1082-9.
43. Kopf D, Bockisch A, Steinert H et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 1997; 46: 39-44.
44. Tenenbaum F, Lumbroso J, Schlumberger M et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995; 36: 1-6.
45. Lastoria S, Maurea S, Vergara E et al. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q J Nucl Med 1995; 39: 145-9.
46. Maurea S, Lastoria S, Caraco C et al. The role of radiolabeled somatostatin analogs in adrenal imaging. Nucl Med Biol 1996; 23: 677-80.
47. Houben K, Dardashti K, Howard BD. PC12 variants deficient in norepinephrine transporter mRNA have wild type activities of several other related transporters. Neurochem Res 1994; 19: 743-51.
48. Ramachandran B, Houben K, Rozenberg YY, Haigh JR, Varpetian A, Howard BD. Differential expression of transporters for norepinephrine and glutamate in wild type, variant, and WNT1-expressing PC12 cells. J Biol Chem 1993; 268: 23891-7.
49. Pederson LC, Lee JE. Pheochromocytoma. Curr Treat Options Oncol 2003; 4: 329-37.
50. Bravo EL. Pheochromocytoma: an approach to antihypertensive management. Ann N Y Acad Sci 2002; 970: 1-10.
51. Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosine and pheochromocytoma. Arch Intern Med 1997; 157: 901-6.
52. Brouwers FM, Lenders JW, Eisenhofer G, Pacak K. Pheochromocytoma as an endocrine emergency. Rev Endocrinol Metab Disord 2003; 4: 121-8.
53. Michaels RD, Hays JH, O'Brian JT, Shakir KM. Pheochromocytoma associated ventricular tachycardia blocked with atenolol. J Endocrinol Invest 1990; 13: 943-7.
54. Moreira SG Jr, Pow-Sang JM. Evaluation and management of adrenal masses. Cancer Control 2002; 9: 326-34.
55. Walther MM. New therapeutic and surgical approaches for sporadic and hereditary pheochromocytoma. Ann N Y Acad Sci 2002; 970: 41-53.
56. Brauckhoff M, Gimm O, Dralle H. Preoperative and surgical therapy in sporadic and familial pheochromocytoma. Front Horm Res 2004; 31: 121-44.
57. Nicolai N. Laparoscopic adrenalectomy. Tumori 2003; 89: 556-9.
58. Martinez Brocca MA, Acosta Delgado D, Quijada D et al. Pheochromocytoma in a pregnant woman with multiple endocrine neoplasia type 2a. Gynecol Endocrinol 2001; 15: 439-42.
59. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma - views on current management. Eur J Surg Oncol 2003; 29: 483-90.
60. Janetschek G, Finkenstedt G, Gasser R et al. Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol 1998; 160: 330-4.
61. Janetschek G, Neumann HP. Laparoscopic surgery for pheochromocytoma. Urol Clin North Am 2001; 28: 97-105.
62. Kaouk JH, Matin S, Bravo EL, Gill IS. Laparoscopic bilateral partial adrenalectomy for pheochromocytoma. Urology 2002; 60: 1100-3.
63. Lairmore TC, Ball DW, Baylin SB, Wells SA. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 1993; 217: 595-601.
64. Sisson JC. Radiopharmaceutical treatment of pheochromocytomas. Ann N Y Acad Sci 2002; 970: 54-60.
65. de Herder WW, Hofland LJ. Somatostatin receptors in pheochromocytoma. Front Horm Res 2004; 31: 145-54.
66. Averbuch SD, Steakley CS, Young RC et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109: 267-73.
67. Jirari A, Charpentier A, Popescu S, Boidin P, Eisenmann B. A malignant primary cardiac pheochromocytoma. Ann Thorac Surg 1999; 68: 565-6.